LIBRELA® is an injectable treatment based on monoclonal antibodies that provides long-lasting relief from osteoarthritis pain in dogs by blocking the NGF protein, thereby improving their mobility and quality of life under veterinary supervision.
Form
LIBRELA® is an innovative solution based on monoclonal antibodies, designed to alleviate pain associated with osteoarthritis in dogs. Its mechanism works by inhibiting nerve growth factor (NGF), a protein essential for transmitting pain signals. By blocking this protein, LIBRELA® effectively reduces pain without the side effects often linked to traditional anti-inflammatory drugs. Administered via subcutaneous injection, this treatment provides prolonged relief for one month. It enhances mobility and improves the quality of life for dogs with arthritis. Administered by a veterinarian, it requires regular follow-up to ensure optimal long-term efficacy.
Bedinvetmab
Must be stored in a refrigerator between 2°C and 8°C.
No known interactions with other medications
Allergies: Do not use in dogs with hypersensitivity to bedinvetmab or any other component of the medication. Growing dogs: Avoid use in puppies or dogs that are still growing, as its impact on development is not well-studied. Pregnancy and lactation: Do not administer to pregnant or lactating females, as the safety of the medication in these cases has not been established.
Urinary tract infections Bacterial skin infections Dermatitis
Help us find loving homes for abandoned animals. Make a donation or become a foster family and change a life forever.
Tel.: (514) 355-8322
Address: 8700 Av. Chaumont,
Anjou, QC H1K 1N6
Copyrights © 2025 Groupe Mon Vet inc. – All rights reserved
Sélectionner votre vétérinaire pour être redirigé à sa boutique en ligne.
Select your veterinarian to be redirected to their online store.